On August 4, 2025, IFF published its financial results for the second quarter of 2025. According to the report, the company saw net sales of $2.76 billion, a decrease of 4% from the previous year. Currency neutral sales increased 3% versus last year, led by growth in the taste and health and biosciences divisions.
“IFF’s second-quarter results reflect the progress we are making to strengthen our business and advance our strategic agenda,” said chief executive officer Erik Fyrwald. “Our teams delivered top-line growth and improved profitability, driven by disciplined execution and a strong focus on productivity.”
The company’s taste segment reported second quarter sales of $631 million, a 6% increase on a currency neutral basis. The scent segment reached sales of $603 million, a 1% increase on a currency neutral basis, with strong growth in fine fragrance and consumer fragrance offset by declines in fragrance ingredients.
“I am increasingly confident in IFF’s long-term outlook,” Fyrwald continued. “With a stronger balance sheet and enhanced financial flexibility, we continue to invest in our highest-return businesses to drive sustainable, profitable growth. The $500 million share repurchase authorization we announced reflects our confidence in IFF’s long-term value and marks a key milestone in our balanced, disciplined capital allocation strategy - prioritizing both reinvestment and returns to shareholders.
“We remain on track to deliver our 2025 commitments we outlined earlier this year, even as the operating environment has become more challenging. While we expect growth to moderate in the second half, we are confident in our ability to deliver profitable growth for the full year. At the same time, we are committed to driving long-term value creation for our shareholders through disciplined execution, strategic investment, and continued productivity.”
